Uncategorized

Aardvark’s next move after clinical hold; Alumis’ verdict on Acelyrin asset

Published

on

Plus, news about Tenaya’s TN-401 and Taiho’s Inqovi.

📉 Aardvark to unblind rare disease trial following clinical hold: The FDA has placed a full clinical hold on the company’s candidate for …

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version